Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | XDH | P47989 | 4/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HES1 | Q14469 | 2/20 | 1.00 |
| ▸ | FANCF | Q9NPI8 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rutin SCHEMBL14369486 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL23244 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL796642 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL20576343 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL2017898 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21424757 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL23663918 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21013017 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21325433 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21699244 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301520-B1 | Oxidative dye | HENKEL AG & CO KGAA (DE) | 2017-03-08 | — | — | EP | disclosed |
| US-20130137767-A1 | Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid | DSM IP ASSETS B.V. (NL) | 2013-05-30 | — | — | US | disclosed |
| EP-2301520-A2 | Oxidative dye | Henkel AG & Co. KGaA (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010006957-A1 | COLORING MEANS COMPRISING NATURAL DYE | HENKEL AG & CO. KGAA (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009060017-A1 | HAIR TREATMENT AGENT COMPRISING TILIROSIDE AND VITAMIN B | HENKEL AG & CO. KGAA (DE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009033833-A2 | COLORING AGENT HAVING NATURAL DYES AND 1,3-DIHYDROXYACETONE | HENKEL AG & CO. KGAA (DE) | 2009-03-19 | — | — | WO | disclosed |
| US-20060198914-A1 | Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders | BIOPLANTA ARZNEIMITTEL GMBH (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1385578-B1 | UTILIZATION OF RUTINS AND AESCINS IN THE TREATMENT OF CIRCULATORY DISTURBANCES OF THE EAR | BRENCH AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050137253-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-23 | — | — | US | disclosed |
| EP-1517667-A2 | COMPOSITIONS AND METHODS FOR REDUCTION OF INFLAMMATORY SYMPTOMS AND/OR BIOMARKERS IN FEMALE SUBJECTS | Galileo Pharmaceuticals, Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040235965-A1 | Utilization of rutins and aescins in the treatment of circulatory disturbances of the ear | BRENCH AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040048919-A1 | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects | ALLOY VENTURES, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004004638-A2 | COMPOSITIONS AND METHODS FOR REDUCTION OF INFLAMMATORY SYMPTOMS AND/OR BIOMARKERS IN FEMALE SUBJECTS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2002047680-A9 | USE OF TOCOPHEROL, METABOLITES OR DERIVATIVES THEREOF OR FLAVONOID METABOLITES OR DERIVATIVES THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TISSUE ISCHEMIA | GALILEO LAB INC (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030144219-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | JOHNSON & JOHNSON CONSUMER INC. | 2003-07-31 | — | — | US | disclosed |
| EP-1294374-A1 | FLAVONE/FLAVANONE DERIVATIVES FOR THE SYSTEMIC TREATMENT AND PROPHYLAXIS OF UV-INDUCED DERMATOSES | Krutmann, Jean (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-20030022818-A1 | Formulations of tocopherols and methods of making and using them | ALLOY VENTURES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020132845-A1 | Compositions and methods for the prevention and treatment of tissue ischemia | ALLOY VENTURES, INC. | 2002-09-19 | — | — | US | disclosed |
| WO-2002047680-A2 | USE OF TOCOPHEROL, METABOLITES OR DERIVATIVES THEREOF OR FLAVONOID METABOLITES OR DERIVATIVES THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TISSUE ISCHEMIA | GALILEO LABORATORIES, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002000214-A1 | FLAVONE/FLAVANONE DERIVATIVES FOR THE SYSTEMIC TREATMENT AND PROPHYLAXIS OF UV-INDUCED DERMATOSES | KRUTMANN JEAN (DE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144219-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | ALOX15B, ALOX5, ALOX12 | KDM4E 4810/4885XDH 2653/4885MAOA 1095/4885 |
| US-20040048919-A1 | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects | PGR, PTGES3, PGRMC1 | KDM4E 3908/4885XDH 4165/4885MAOA 791/4885 |
| US-20060198914-A1 | Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders | CRH, NLN, TPH2 | KDM4E 3426/4885XDH 664/4885MAOA 867/4885 |
| US-20050137253-A1 | Formulations and methods for treatment or amelioration of inflammatory conditions | ALOX15B, ALOX5, ALOX12 | KDM4E 4810/4885XDH 2653/4885MAOA 1095/4885 |
| US-20040235965-A1 | Utilization of rutins and aescins in the treatment of circulatory disturbances of the ear | ECHS1, CIAPIN1, WFS1 | KDM4E 4584/4885XDH 1529/4885MAOA 2418/4885 |
| US-20020132845-A1 | Compositions and methods for the prevention and treatment of tissue ischemia | NDUFB5, NDUFB3, EBP | KDM4E 4055/4885XDH 933/4885MAOA 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.